Opicapone Administration Avoiding Quinidine Interactions
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a significant unmet need for methods to administer opicapone, a catechol-O-methyltransferase inhibitor, to patients who are also taking quinidine, as their co-administration can lead to increased exposure and adverse drug events due to drug-drug interactions, with mechanisms often unknown.
Innovation Solution
Administering a therapeutically effective amount of opicapone while informing patients or medical care workers to avoid co-administration with quinidine, or discontinuing quinidine treatment before administering opicapone to prevent interactions.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Adaptability or versatility
If co-administration of opicapone and quinidine is performed, then treatment of Parkinson's disease and other conditions can be provided, but increased exposure to opicapone and adverse drug events occur due to drug-drug interactions
Solution Approach 1:
The patent applies preliminary anti-action by proactively identifying and preventing the harmful interaction between opicapone and quinidine before it can cause adverse effects. The method involves checking for quinidine co-administration and taking preventive measures (discontinuation or avoidance) before the dangerous pharmacokinetic interaction occurs, thereby blocking the harmful pathway while preserving the therapeutic benefits of opicapone when used appropriately
2Object-affected harmful factors
If quinidine is discontinued before administering opicapone, then adverse drug events are avoided, but treatment continuity for the original condition may be interrupted
Solution Approach 1:
The patent applies preliminary action by implementing a systematic screening process that identifies patients at risk of quinidine-opicapone interactions before opicapone is administered. By checking medication histories and providing advance warning or arranging alternative therapies before the interaction occurs, the method prevents adverse events while minimizing treatment interruptions through proactive patient management
3Object-affected harmful factors
If information about quinidine interaction is provided to patients or medical care workers, then co-administration can be avoided, but complexity of treatment management increases
Solution Approach 1:
The patent applies feedback by implementing an information provision system that alerts patients and medical care workers about the quinidine-opicapone interaction risk. This feedback loop enables informed decision-making at the point of care, allowing healthcare providers and patients to adjust treatment plans appropriately while maintaining clear, actionable guidance that does not unnecessarily complicate treatment management
Data Source
AI summary
Provided are methods of administering a catechol-O-methyltransferase (COMT) inhibitor chosen from opicapone, or a pharmaceutically acceptable salt and/or isotopic variant thereof, to a patient in need thereof wherein the patient is already being administered quinidine or is suffering from a disease or disorder treatable by quinidine.